# BBOT (Bridgebio Oncology Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Bridgebio Oncology Therapeutics, Inc. reported $346.2M in total assets and a net loss of $171.5M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/BBOT
- Markdown: https://convexityos.com/fundamentals/BBOT.md
- SEC CIK: 0001869105
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:45 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001869105&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$187.3M | Operating profit |
| Net Income | FY 2025 | -$171.5M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$2.14 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$151.0M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $193.9M | Total debt: $2.38M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $121.2M | $73.11M | -- |
| Total Operating Expenses | $145.8M | $80.86M | -- |
| **Operating Income** | -$145.8M | -$80.86M | -$42K |
| **EBITDA** | -$145.5M | -$80.66M | -- |
| Interest Income | $11.34M | $8.45M | -- |
| Income Tax Expense | $0 | $0 | -- |
| **Net Income** | -$134.0M | -$74.28M | -$42K |
| Basic EPS | -$4.30 | -$5,756.41 | -- |
| **Diluted EPS** | -$4.30 | -$5,756.41 | -- |
| Basic Shares Outstanding | 31.1M | 12.9K | -- |
| Diluted Shares Outstanding | 31.1M | 12.9K | -- |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $29.59M | $49.23M | $39.80M | $38.07M | $35.05M | $27.44M | $20.64M | -- |
| Total Operating Expenses | $37.49M | $60.19M | $46.18M | $43.41M | $49.18M | $30.09M | $23.14M | -- |
| **Operating Income** | -$37.49M | -$60.19M | -$46.18M | -$43.41M | -$49.18M | -$30.09M | -$23.14M | -$21.88M |
| **EBITDA** | -$37.39M | -$60.09M | -$46.10M | -$43.32M | -$49.08M | -$29.99M | -$23.08M | -- |
| Interest Income | $3.26M | $3.55M | $3.94M | $4.42M | $3.44M | $2.07M | $1.99M | $2.25M |
| Income Tax Expense | $0 | $0 | -- | $0 | $0 | $0 | $0 | -- |
| **Net Income** | -$34.18M | -$56.45M | -$42.11M | -$38.80M | -$44.76M | -$28.43M | -$22.05M | -$19.69M |
| Basic EPS | -$0.43 | -$705.20 | -$526.11 | -- | -$1.03 | -$566.46 | -$54.23 | -- |
| **Diluted EPS** | -$0.43 | -$705.20 | -$526.11 | -- | -$1.03 | -$566.46 | -$54.23 | -- |
| Basic Shares Outstanding | 80.2M | 80.1M | 80.0K | -- | 43.5M | 50.2M | 406.7K | -- |
| Diluted Shares Outstanding | 80.2M | 80.1M | 80.0K | -- | 43.5M | 50.2M | 406.7K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $373.7M | $30.85M | $0 |
| Short-Term Investments | $51.77M | $124.8M | -- |
| **Cash & Short-Term Investments** | $425.5M | $155.6M | $0 |
| **Total Current Assets** | $432.4M | $158.7M | -- |
| Property, Plant & Equipment, Net | $956K | $490K | -- |
| Long-Term Investments | $0 | -- | -- |
| Other Non-Current Assets | $12.57M | $4.99M | -- |
| **Total Non-Current Assets** | $15.98M | $5.61M | -- |
| **Total Assets** | $448.4M | $164.3M | $333K |
| Accounts Payable | $1.37M | $3.07M | -- |
| **Total Current Liabilities** | $35.04M | $19.58M | $396K |
| **Total Non-Current Liabilities** | $2.24M | $0 | $0 |
| **Total Liabilities** | $37.28M | $19.58M | $396K |
| **Total Debt (incl. Leases)** | $2.77M | -- | -- |
| Common Stock | $8.0K | $0 | -- |
| Retained Earnings | -$356.6M | -$222.5M | -$89K |
| Accumulated Other Comp. Income | $16K | $348K | -- |
| **Total Stockholders' Equity** | $411.1M | -$178.6M | -$115.6M |
| Total Equity | $411.1M | -$178.6M | -$115.6M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $76.48M | $54.06M | $52.66M | $373.7M | $408.7M | $664K | $963K | $30.85M |
| Short-Term Investments | $117.4M | $171.6M | $199.6M | $51.77M | $59.54M | -- | -- | $124.8M |
| **Cash & Short-Term Investments** | $315.3M | $344.1M | $388.9M | $425.5M | $468.3M | $664K | $963K | $155.6M |
| **Total Current Assets** | $208.3M | $242.4M | $266.5M | $432.4M | $476.0M | $877K | $1.24M | $158.7M |
| Property, Plant & Equipment, Net | $815K | $878K | $938K | $956K | $827K | -- | -- | $490K |
| Long-Term Investments | $121.5M | $118.4M | $136.6M | $0 | -- | -- | -- | -- |
| Other Non-Current Assets | $13.50M | $12.79M | $11.24M | $12.57M | $5.38M | -- | -- | $4.99M |
| **Total Non-Current Assets** | $137.9M | $134.3M | $151.1M | $15.98M | $8.78M | $196.5M | $194.4M | $5.61M |
| **Total Assets** | $346.2M | $376.7M | $417.6M | $448.4M | $484.8M | $197.4M | $195.7M | $164.3M |
| Accounts Payable | $10.26M | $6.73M | $12.09M | $1.37M | $3.65M | -- | -- | $3.07M |
| **Total Current Liabilities** | $51.03M | $51.63M | $43.26M | $35.04M | $35.71M | $2.63M | $1.87M | $19.58M |
| **Total Non-Current Liabilities** | $1.81M | $1.96M | $2.11M | $2.24M | $2.38M | $5.52M | $5.52M | $0 |
| **Total Liabilities** | $52.84M | $53.59M | $45.37M | $37.28M | $38.09M | $8.15M | $7.39M | $19.58M |
| **Total Debt (incl. Leases)** | $2.38M | $2.51M | $2.64M | $2.77M | $2.89M | -- | -- | -- |
| Common Stock | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | -- | -- | $0 |
| Retained Earnings | -$489.3M | -$455.1M | -$398.7M | -$356.6M | -$317.8M | -$7.27M | -$6.15M | -$222.5M |
| Accumulated Other Comp. Income | -$1.70M | -$959K | -$981K | $16K | $36K | -- | -- | $348K |
| **Total Stockholders' Equity** | $293.4M | $323.1M | $372.3M | $411.1M | $446.7M | -$227.7M | -$200.0M | -$178.6M |
| Total Equity | $293.4M | $323.1M | $372.3M | $411.1M | $446.7M | -$227.7M | -$200.0M | -$178.6M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$134.0M | -$74.28M | -$42K |
| Depreciation & Amortization | $280K | $208K | -- |
| Stock-Based Compensation | $5.87M | $4.42M | -- |
| Change in Payables | -$1.84M | $2.50M | -- |
| **Operating Cash Flow** | -$113.9M | -$55.03M | -- |
| Capital Expenditure | -$606K | -$49K | -- |
| **Free Cash Flow** | -$114.5M | -$55.08M | -- |
| Purchases of Investments | -$83.92M | -$154.4M | -- |
| **Investing Cash Flow** | $73.33M | -$120.5M | -- |
| Common Stock Issued | $112.3M | -- | -- |
| **Financing Cash Flow** | $383.4M | $206.3M | -- |
| **Net Change in Cash** | $342.8M | $30.73M | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$34.18M | -$56.45M | -$42.11M | -$38.80M | -$44.76M | -$28.43M | -$22.05M | -$19.69M |
| Depreciation & Amortization | $100K | $100K | $74K | $84K | $100K | $100K | $54K | -- |
| Stock-Based Compensation | $4.75M | $7.23M | $3.87M | $2.95M | $1.43M | $36K | $627K | $587K |
| Change in Payables | $3.53M | -$5.33M | $10.69M | -$2.42M | $2.09M | -$2.05M | $537K | -- |
| **Operating Cash Flow** | -$28.36M | -$44.36M | -$35.92M | -$42.23M | -$28.77M | -$23.29M | -$19.60M | -$15.04M |
| Capital Expenditure | -$13K | -$47K | -$24K | -$73K | -$140K | -$231K | -$162K | -- |
| **Free Cash Flow** | -$28.38M | -$44.41M | -$35.94M | -$42.31M | -$28.91M | -$23.52M | -$19.76M | -- |
| Purchases of Investments | -$16.95M | -$7.54M | -$311.6M | -$21.04M | -$4.46M | -$33.98M | -$24.43M | -- |
| **Investing Cash Flow** | $50.34M | $45.73M | -$285.4M | $7.77M | $40.55M | $9.64M | $15.37M | $25.56M |
| Common Stock Issued | $0 | $0 | $112.3M | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $442K | $37K | $295K | -$586K | $365.4M | $18.96M | -$404K | $52K |
| **Net Change in Cash** | $22.42M | $1.41M | -$321.0M | -$35.05M | $377.2M | $5.30M | -$4.63M | $10.57M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -32.6% | -- | -- |
| Return on Assets (ROA) | -29.9% | -45.2% | -12.5% |
| Current Ratio | 12.34x | 8.10x | -- |
| Quick Ratio | 12.14x | 7.95x | 0.00x |
| Debt to Equity | 0.01x | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -58.5% | -56.4% | -41.4% | -32.6% | -25.7% | -- | -- | -- |
| Return on Assets (ROA) | -49.5% | -48.3% | -36.9% | -29.9% | -23.7% | -44.3% | -41.3% | -45.2% |
| Current Ratio | 4.08x | 4.69x | 6.16x | 12.34x | 13.33x | 0.33x | 0.66x | 8.10x |
| Quick Ratio | 6.18x | 6.66x | 8.99x | 12.14x | 13.11x | 0.25x | 0.51x | 7.95x |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
